Compare Hims and Hers Health Inc (HIMS) vs Ulta Beauty Inc (ULTA) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

ULTA stock trades at $545.48, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings that beat estimates and raised its 2026 outlook, driven by e-commerce growth. Key financials show robust profitability with a 9.34% net income margin and 46.12% ROE, though revenue growth has moderated recently. Analyst sentiment is positive with a consensus price target of $624.93, implying potential upside from current levels.

The outlook for ULTA is favorable, supported by raised guidance and strategic initiatives in omnichannel and wellness categories. Investment opportunities include valuation expansion if execution meets raised expectations. Key risks include margin pressure from promotions, flat store traffic, and competitive pressures in the beauty retail space that could challenge future earnings growth.